Elsevier

Clinical Therapeutics

Volume 28, Issue 10, October 2006, Pages 1712-1725
Clinical Therapeutics

Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data

https://doi.org/10.1016/j.clinthera.2006.10.004Get rights and content

Abstract

Objective:

This study evaluated the impact on adherence, hypoglycemic events, resource utilization, and the associated health care costs of converting from administration of insulin therapy by a vial/syringe to an insulin analogue pen device in patients with type 2 diabetes mellitus.

Methods:

This pre-post analysis used an integrated medical and pharmacy claims database containing information for >40 million covered lives from 57 managed care health plans in the United States. Adults with a diagnosis of type 2 diabetes whose treatment was converted from conventional human or analogue insulin injection (vial/syringe) to a prefilled insulin analogue pen from July 2001 through December 2002, with no use of an insulin analogue pen device in the preceding 6 months, were identified and analyzed retrospectively. The primary end points were adherence (as measured by a medication possession ratio [MPR] ≥80%); the odds ratio (OR) for hypoglycemic events requiring health care resource utilization and resulting in a claim; the association between adherence and hypoglycemic events; and all-cause, hypoglycemia-attributable (HA), and diabetes-attributable (DA) health care costs.

Results:

A total of 1156 subjects were identified and analyzed (mean [SD] age, 45.4 [13.7] years; 53.8% male; previous insulin vial use: 595 [51.5%] human, 561 [48.5%] analogue). Medication adherence was significantly improved after conversion to the insulin pen device (from 62% to 69%; P < 0.01). The proportion of subjects considered adherent was significantly higher in the period after the conversion compared with before the conversion (54.6% vs 36.1%, respectively; P < 0.01). The likelihood of experiencing a hypoglycemic event was significantly reduced after conversion (OR = 0.50; 95% CI, 0.37–0.68; P < 0.05), and the incidence of hypoglycemia in subjects with an MPR ≥80% de creased by nearly two thirds (incident rate ratio = 0.35; 95% CI, 0.11–0.81; P < 0.05). There were significant decreases in HA emergency department visits (OR = 0.44; 95% CI, 0.21–0.92; P < 0.05) and physician visits (OR = 0.39; 95% CI, 0.24–0.64; P < 0.05), whereas HA-related hospitalizations and outpatient visits remained similar after conversion. Total mean all-cause annual treatment costs were reduced by $1590 per patient (from $16,359 to $14,769; P < 0.01). Annual HA costs were reduced by $788 per patient (from $1415 to $627; P < 0.01), predominantly as a result of decreased hospitalization costs (from $857 to $288; P < 0.01). Annual DA costs were reduced by $600 per patient (from $8827 to $8227; P < 0.01).

Conclusions:

Among these patients with type 2 diabetes treated in a managed care setting, a switch from administration of insulin therapy by vial/syringe to a prefilled insulin analogue pen device was associated with improved medication adherence, fewer claims for hypoglycemic events, reduced emergency department and physician visits, and lower annual treatment costs.

References (54)

  • WildS. et al.

    Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030

    Diabetes Care

    (2004)
  • National Diabetes Fact Sheet, United States 2005

    (2006)
  • HarrisM.I. et al.

    Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey (NHANES) 1988–1994

    Diabetes Care

    (1998)
  • StrattonI.M. et al.

    Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study

    BMJ

    (2000)
  • BrownJ.B. et al.

    The progressive cost of complications in type 2 diabetes mellitus

    Arch Intern Med

    (1999)
  • MenzinJ. et al.

    Potential short-term economic benefits of improved glycemic control: A managed care perspective

    Diabetes Care

    (2001)
  • WagnerE.H. et al.

    Effect of improved glycemic control on health care costs and utilization

    JAMA

    (2001)
  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

    Lancet

    (1998)
  • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

    N Engl Med

    (1993)
  • ResnickH.E. et al.

    Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999–2002: The National Health and Nutrition Examination Survey

    Diabetes Care

    (2006)
  • SpannS.J. et al.

    Management of type 2 diabetes in the primary care setting: A practice-based research network study

    Ann Fam Med

    (2006)
  • SaadinneJ.B. et al.

    Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002

    Ann Intern Med

    (2006)
  • MarreM.

    Before oral agents fail: The case for starting insulin early

    Int J Obes Relat Metab Disord

    (2002)
  • RollaA.R. et al.

    Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues

    Clin Ther

    (2005)
  • Standards of medical care in diabetes

    Diabetes Care

    (2004)
  • Update on insulin injection devices

    (2006)
  • KorytkowskiM. et al.

    FlexPen: Addressing issues of confidence and convenience in insulin delivery

    Clin Ther

    (2005)
  • CoonrodB.A.

    Insulin syringes and pens: Finding the best match for your patients' needs

    Clin Diabetes

    (1997)
  • KorytkowskiM. et al.

    A multicenter, randomized, openlabel, comparative, two-period crossover trial of prefer ence, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus

    Clin Ther

    (2003)
  • NiskanenL. et al.

    Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus

    Clin Ther

    (2004)
  • AsakuraT. et al.

    Assessment of dose selection attributes with audible notification in insulin pen devices

    Diabetes Technol Ther

    (2005)
  • SummersK.I.T. et al.

    Preference for insulin delivery systems among current insulin users and nonusers

    Clin Ther

    (2004)
  • GraffM.R. et al.

    Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe

    Clin Ther

    (1998)
  • SucicM. et al.

    Patient acceptance and reliability of new Humulin/Humalog 3.0 mL prefilled insulin pen in ten Croatian diabetes centres

    Med Sci Monit

    (2002)
  • KadiriA. et al.

    Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents.

    Diabetes Res Oin Pract

    (1998)
  • AlbanoS.

    Assessment of quality of treatment in insulin-treated patients with diabetes using a pre-filled insulin pen

    Acta Biomed Ateneo Parmense

    (2004)
  • RubinR.R. et al.

    Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies

    Diabetes Care

    (2004)
  • Cited by (247)

    View all citing articles on Scopus
    View full text